Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapeutic modulation of NKG7 in CD8+ T cells increases anti-tumor cytotoxicity and improves response to immune checkpoint inhibitors

ABSTRACT: Therapeutic modulation of NKG7 in CD8+ T cells increases anti-tumor cytotoxicity and improves response to immune checkpoint inhibitors

PROVIDER: PRJNA689600 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13350118_1.fastq.gz	Fastqsanger.gz
	SRR13350118_2.fastq.gz	Fastqsanger.gz
	SRR13350119_1.fastq.gz	Fastqsanger.gz
	SRR13350119_2.fastq.gz	Fastqsanger.gz
	SRR13350120_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Therapeutic modulation of NKG7 in CD8+ T cells increases anti-tumor cytotoxicity and improves response to immune checkpoint inhibitors

Project description:Monoclonal antibodies that block PD-1/PD-L1 inhibitory signaling have been successfully used to treat a variety of solid tumor malignancies, but only a subset of patients benefit from this treatment. It remains unclear why the majority of patients fail to respond and what other limiting factors are at play. Here we show that natural killer cell granule protein-7 (NKG7) is critical for the anti-tumor activity of CD8+ T cells and response to anti-PD-1 therapy. We performed single-cell RNA sequencing analysis of peripheral CD8+ T cells from patients treated with anti-PD-1 and found that NKG7 gene expression was decreased in the non-responding patients.

2022-02-18 | GSE164237 | GEO

G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered TCR-T cells against hepatocellular carcinoma

Project description:Engineered T cells transiently expressing tumor-targeting receptors are an attractive form of engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term adverse side-effects. However, multiple rounds of treatment are often required, increasing patient discomfort and cost. To mitigate this, we sought to improve the antitumor activity of transient engineered T cells by screening a panel of small molecules targeting epigenetic regulators for their effect on T cell cytotoxicity. Using a model for engineered T cells targetting hepatocellular carcinoma, we find that short-term inhibition of G9a/GLP increases T cell antitumor activity in in vitro models and an orthotopic mouse model. G9a/GLP inhibition increases granzyme expression without terminal T cell differentiation or exhaustion and results in specific changes in expression of genes and proteins involved in pro-inflammatory pathways, T cell activation and cytotoxicity.

2023-01-19 | PXD039542 | JPOST Repository

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma

Project description:Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma

| PRJNA874707 | ENA

An outdoor access period improves chicken caecal microbiota and potentially increases micronutrient biosynthesis

Project description:An outdoor access period improves chicken caecal microbiota and potentially increases micronutrient biosynthesis

| PRJEB53430 | ENA

Colitis associated with immune checkpoint inhibitors

Project description:Colitis associated with immune checkpoint inhibitors

| PRJNA849977 | ENA

Concurrent delivery of immune checkpoint blockade improves tumor microenvironment for vaccine-generated immunity

Project description:Concurrent delivery of immune checkpoint blockade improves tumor microenvironment for vaccine-generated immunity

| PRJNA741385 | ENA

Concurrent delivery of immune checkpoint blockade improves tumor microenvironment for vaccine-generated immunity

Project description:Neoantigen vaccines aiming to induce and amplify tumor-specific T cell responses have received promising anti-tumor effect in early clinical trials. However, the underlying mechanism regarding response or resistance to this treatment remains unclear. Here, we observed that neoantigen vaccine-generated T cells could synergize with immune checkpoint blockade (ICB) for effective tumor control. Specifically, we performed single-cell sequencing on over 100,000 T cells and uncovered that combined therapy induced a novel antigen-specific CD8 T cell population with active chemokine signaling (Cxcr3+/Ccl5+), lower co-inhibitory receptor expression (Lag3-/Havcr2-) and higher cytotoxicity (Fasl+/Gzma+). Furthermore, the generation of antigen specific T cells in the drain lymph node is required for combination treatment mediated therapeutic effect. Signature genes of this unique population is associated with T cell clonal frequency and better survival in human. Our study comprehensively profiled the dynamics of tumor infiltrated T cells during neoantigen vaccine and ICB treatments, and high-dimensionally identified neoantigen-reactive T cell signatures for future development of better therapeutic strategies.

2022-01-10 | GSE178881 | GEO

Colitis associated with immune checkpoint inhibitors [blood_cells]

Project description:Colitis associated with immune checkpoint inhibitors [blood_cells]

| PRJNA849982 | ENA

Colitis associated with immune checkpoint inhibitors [tissue_nuclei]

Project description:Colitis associated with immune checkpoint inhibitors [tissue_nuclei]

| PRJNA849980 | ENA

Colitis associated with immune checkpoint inhibitors [tissue_cells]

Project description:Colitis associated with immune checkpoint inhibitors [tissue_cells]

| PRJNA849981 | ENA